Chemotherapy treatment for anti-Hu paraneoplastic syndrome without active malignancy;Traitement par chimiothérapie d'un syndrome neurologique paranéoplasique anti-Hu sans cancer actif associé

Revue Neurologique

Volumn 162, Issue 8-9, 2006, Pages 862-865

  Gaillard, N ^a,c   Charif, M ^a   Carlander, B ^a   Pujol, J L ^b   Touchon, J ^a  

^a GUI DE CHAULIAC HOSPITAL   (France)

^b HÔPITAL ARNAUD DE VILLENEUVE   (France)

^c NONE   (France)

Author keywords

Anti Hu antibodies; Chemotherapy; FDG PET scan; Paraneoplastic neurological syndrome; Treatment

Indexed keywords

CISPLATIN; ETOPOSIDE;

ADULT; ARTICLE; CASE REPORT; DISEASE ASSOCIATION; DISEASE COURSE; EMPIRICISM; ENCEPHALITIS; EVALUATION; HUMAN; MALE; MEDICAL RESEARCH; PARANEOPLASTIC SYNDROME;

EID: 33748494646     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0035-3787(06)75091-3     Document Type: Article

References (13)

1. CHARTRAND-LEFEBVRE C, HOWARTH N, GRENIER P, KEIME F, ORCEL B, BEIGELMAN C. (1998). Association of small cell lung cancer and the anti-Hu paraneoplastic syndrome: radiographic and CT findings. AJR Am J Roentgenol, 170: 1513-1517.
2. DARNELL RB, POSNER JB. (2003). Paraneoplastic syndromes involving the nervous system. N Engl J Med, 349: 1543-1554.
3. GRAUS F, KEIME-GUIBERT F, REÑE R et al. (2001). Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain, 24: 1138-1148.
4. GRAUS F, DELATTRE J.Y, ANTOINE JC et al. (2004). Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry, 75: 1135-1140.
5. HUMAYUN GULTEKIN S, ROSENFELD M.R, VOLTZ R, EICHEN J, POSNER J.B, DALMAU J. (2000). Paraneoplastic limbic encephalitis: neurological and tumour association in 50 patients. Brain, 123: 1481-1494.
6. KEIME-GUIBERT F, GRAUS F, BROËT P et al. (1999). Clinical outcome of patients with anti-Hu-associated encephalomyelitis after treatment of the tumor. Neurology, 53: 1719.
7. KEIME-GUIBERT F, GRAUS F, FLEURY A et al. (2000). Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, Anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone. J Neurol Neurosurg Psychiatry, 68: 479-482.
8. LINKE R, SCHROEDER M, HELMBERGER T, VOLTZ R. (2004). Antibody-positive paraneoplastic neurologic syndromes: value of CT and PET for tumor diagnosis. Neurology, 63: 282-286.
9. LUCCHINETTI CF, KIMMEL DW, LENNON VA. (1998). Paraneoplastic and oncologic profiles of patients seropositive for type 1 antineuronal nuclear autoantibodies. Neurology, 50: 652-657.
10. SILLEVIS SMITT P, GREFKENS J, DE LEEUW B, VAN DEN BENT M, VAN PUTTEN HOOIJKAAS H, VECHT C. (2002). Survival and outcome in 73 anti-Hu positive patients with paraneoplastic encephalomyelitis/sensory neuronopathy. J Neurol, 249: 745-753.
11. UCHUYA M, GRAUS F, VEGA F, RENE R, DELATTRE JY. (1996). Intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with antineuronal autoantibodiens. J Neurol Neurosurg Psychiatry, 60: 388-392.
12. VERNINO S, O'NEILL BP, MARKS RS, O'FALLON JR, KIMMEL DW. (2004). Immunomodulatory treatment trial for paraneoplastic neurological disorders. Neuro-Oncology, 6: 55-62.
13. YOUNES-MHENNI S, JANIER MF, CINOTTI L et al. (2004). FDG-PET improves tumour detection in patients with paraneoplastic neurological syndromes. Brain, 127: 2331-2338.